Amphetamine disrupts P50 suppression in normal subjects

Biological Psychiatry

Volumn 46, Issue 7, 1999, Pages 990-996

  Light, Gregory A ^a   Malaspina, Dolores ^b   Geyer, Mark A ^a   Luber, Bruce M ^b   Coleman, Eliza A ^b   Sackeim, Harold A ^b   Braff, David L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Amphetamine; EEG; Event related potential; Gating; Monoamines; Schizophrenia; Suppression

Indexed keywords

AMPHETAMINE; PLACEBO;

ADULT; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; DRUG EFFECT; ELECTROENCEPHALOGRAM; EVENT RELATED POTENTIAL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADRENERGIC AGENTS; ADULT; AROUSAL; ATTENTION; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBRAL CORTEX; DEXTROAMPHETAMINE; DOPAMINE AGENTS; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; HUMANS; MALE; REFERENCE VALUES; SCHIZOPHRENIA;

EID: 0032828522     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00034-7     Document Type: Article

References (57)

1. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry. 32:1992;607-616.
2. Adler L.E., Hoffer L., Nagamoto H.T., Waldo M.C., Kisley M.A., Giffith J.M. Yohimbine impairs P50 auditory sensory gating in normal subjects. Neuropsychopharmacol. 10:1994;249-257.
3. Adler L.E., Pachtman E., Franks R.D., Pecevich M., Waldo M.C., Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry. 17:1982;639-654.
4. Adler L.E., Pang K., Gerhardt G., Rose G.M. Modulation of the gating of auditory evoked potentials by norepinephrine Pharmacological evidence obtained using a selective neurotoxin . Biol Psychiatry. 24:1988;179-190.
5. Adler L.E., Rose G., Freedman R. Neurophysiological studies of sensory gating in rats Effects of amphetamine, phencyclidine, and haloperidol . Biol Psychiatry. 21:1986;787-798.
6. Angrist B., Corwin J., Bartlik B., Cooper T. Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biol Psychiatry. 22:1987;1357-1368.
7. Baker N., Adler L.E., Franks R.D., et al. Neurophysiological assessment of sensory gating in psychiatric inpatients Comparison between schizophrenia and other diagnoses . Biol Psychiatry. 22:1987;603-617.
8. Baker N.J., Staunton M., Adler L.E., et al. Sensory gating deficits in psychiatric inpatients relation to catecholamine metabolites in different diagnostic groups . Biol Psychiatry. 27:1990;519-528.
9. Bickford-Wimer P.C., Nagamoto H., Johnson R., et al. Auditory sensory gating in hippocampal neurons A model system in the rat . Biol Psychiatry. 27:1990;183-192.
10. Boutros N.N., Overall J., Zouridakis G. Test-retest reliability of the P50 mid-latency auditory evoked response. Psychiatry Res. 39:1991;181-192.
11. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry. 47:1990;181-188.
12. Canuso C.M., Goldstein J.M., Green A.I. The evaluation of women with schizophrenia. Psychopharmacol Bull. 34:1998;271-277.
13. Cardenas V.A., Gerson J., Fein G. The reliability of P50 suppression as measured by the conditioning/testing ratio is vastly improved by dipole modeling. Biol Psychiatry. 33:1993;335-344.
14. Clementz B.A., Geyer M.A., Braff D.L. Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schizophr Res. 30:1998;71-80.
15. Clementz B.A., Geyer M.A., Braff D.L. Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry. 155:1998;1691-1694.
16. Clementz B.A., Blumenfeld L.D., Cobb S. The gamma band response may account for poor P50 suppression in schizophrenia. Neuroreport. 8:1997;3889-3893.
17. Clementz B.A., Geyer M.A., Braff D.L. P50 suppression among schizophrenia and normal comparison subjects A methodological analysis . Biol Psychiatry. 41:1997;1035-1044.
18. Cohen J. The earth is round (p<.05). Am Psychologist. 49:1994;997-1003.
19. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. J Neuropsychiatry Clin Neurosci. 8:1996;223-226.
20. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
21. Erwin R.J., Mawhinney-Hee M., Gur R.C., Gur R.E. Midlatency auditory evoked responses in schizophrenia. Biol Psychiatry. 30:1991;430-442.
22. Farde L. Brain imaging of schizophrenia - the dopamine hypothesis. Schizophr Res. 28:1997;157-162.
23. Franks R.D., Adler L.E., Waldo M.C., Alpert J., Freedman R. Neurophysiological studies of sensory gating in mania Comparison with schizophrenia . Biol Psychiatry. 18:1983;989-1005.
24. Freedman R., Coon H., Myles-Worsley M., et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A. 94:1997;587-592.
25. Freedman R., Adler L.E., Myles-Worsley M., et al. Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Human recordings, computer simulation, and an animal model. Arch Gen Psychiatry. 53:1996;1114-1121.
26. Freedman R., Adler L.E., Waldo M.C., Pachtman E., Franks R.D. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia Comparison of medicated and drug-free patients . Biol Psychiatry. 18:1983;537-551.
27. Hetrick W.P., Sandman C.A., Bunney W.E. Jr, Jin Y., Potkin S.G., White M.H. Gender differences in gating of the auditory evoked potential in normal subjects. Biol Psychiatry. 39:1996;51-58.
28. Jin Y., Potkin S.G., Patterson J.V., Sandman C.A., Hetrick W.P., Bunney W.E. Jr. Effects of P50 temporal variability on sensory gating in schizophrenia. Psychiatry Res. 70:1997;71-81.
29. Johnson R.G., Stevens K.E., Rose G.M. 5-Hydroxytryptamine2 receptors modulate auditory filtering in the rat. J Pharmacol Exp Ther. 285:1998;643-650.
30. Judd L.L., McAdams L., Budnick B., Braff D.L. Sensory gating deficits in schizophrenia New results . Am J Psychiatry. 149:1992;488-493.
31. Light G.A., Braff D.L. The "incredible shrinking" P50 event-related potential. Biol Psychiatry. 43:1998;918-920.
32. Malaspina D., Colemann E.A., Quitkin M., et al. Effects of pharmacologic catecholamine manipulation on smooth pursuit eye movements in normals. Schiz Res. 13:1994;151-159.
33. Mansbach R.S., Geyer M.A., Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl). 94:1988;507-514.
34. Nagamoto H.T., Adler L.E., Hea R.A., Griffith J.M., McRae K.A., Freedman R. Gating of auditory P50 in schizophrenics Unique effects of clozapine . Biol Psychiatry. 40:1996;181-188.
35. Nagamoto H.T., Adler L.E., McRae K.A., et al. Auditory P50 in schizophrenics on clozapine Improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol . Neuropsychobiology. 39:1999;10-17.
36. Nagamoto H.T., Adler L.E., Waldo M.C., Freedman R. Sensory gating in schizophrenics and normal controls Effects of changing stimulation interval . Biol Psychiatry. 25:1989;549-561.
37. Salem J.E., Kring A.M. The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Clin Psychol Rev. 18:1998;795-819.
38. Sedvall G. The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology. 7:1992;41-54.
39. Sedvall G. PET imaging of dopamine receptors in human basal ganglia Relevance to mental illness . Trends Neurosci. 13:1990;302-308.
40. Sedvall G., Pauli S., Farde L., Karlsson P., Nyberg S., Nordstrom A.L. Recent developments in PET scan imaging of neuroreceptors in schizophrenia. Isr J Psychiatry Relat Sci. 32:1995;22-29.
41. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
42. Siegel C., Waldo M., Mizner G., Adler L.E., Freedman R. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. Arch Gen Psychiatry. 41:1984;607-612.
43. Snyder S.H. Biochemical factors in schizophrenia. Hosp Pract. 12:1977;133-140.
44. Snyder S.H. The dopamine hypothesis of schizophrenia Focus on the dopamine receptor . Am J Psychiatry. 133:1976;197-202.
45. Snyder S.H. Amphetamine psychosis A "model" schizophrenia mediated by catecholamines . Am J Psychiatry. 130:1973;61-67.
46. Stevens K.E., Freedman R., Collins A.C., et al. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology. 15:1996;152-162.
47. Stevens K.E., Fuller L.L., Rose G.M. Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating. Brain Res. 555:1991;91-98.
48. Stevens K.E., Luthman J., Lindqvist E., Johnson R.G., Rose G.M. Effects of neonatal dopamine depletion on sensory inhibition in the rat. Pharmacol Biochem Behav. 53:1996;817-823.
49. Stevens K.E., Meltzer J., Rose G.M. Disruption of sensory gating by the alpha 2 selective noradrenergic antagonist yohimbine. Biol Psychiatry. 33:1993;130-132.
50. Swerdlow N.R., Auerbach P., Monroe S.M., Hartston H., Geyer M.A., Braff D.L. Men are more inhibited than women by weak prepulses. Biol Psychiatry. 34:1993;253-260.
51. Swerdlow N.R., Mansbach R.S., Geyer M.A., Pulvirenti L., Koob G.F., Braff D.L. Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology. 100:1990;413-416.
52. Waldo M., Myles-Worsley M., Madison A., Byerley W., Freedman R. Sensory gating deficits in parents of schizophrenics. Am J Med Genet. 60:1995;506-511.
53. Waldo M.C., Adler L.E., Freedman R. Defects in auditory sensory gating and their apparent compensation in relatives of schizophrenics. Schizophr Res. 1:1988;19-24.
54. Waldo M.C., Carey G., Myles-Worsley M., et al. Codistribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res. 39:1991;257-268.
55. Waldo M.C., Cawthra E., Adler L.E., et al. Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings. Schizophr Res. 12:1994;93-106.
56. Ward P.B., Hoffer L.D., Liebert B.J., Catts S.V., O'Donnell M., Adler L.E. Replication of a P50 auditory gating deficit in Australian patients with schizophrenia. Psychiatry Res. 64:1996;121-135.
57. Wiesel F.A. Positron emission tomography in psychiatry. Psychiatr Dev. 7:1989;19-47.